Phase II Trial of Subcutaneous Interleukin-2, Subcutaneous Interferon-α, Intravenous Combination Chemotherapy, and Oral Tamoxifen in the Treatment of Metastatic Melanoma: Final Results of Cancer Biotherapy Research Group 94-11

Abstract

This outpatient regimen was associated with significant toxicity including a 7% rate of possible treatment-related death. Tumor regression rates and survival were similar to results reported for chemotherapy alone, or inpatient IL-2-based therapy, but did not suggest an improvement in outcome.

Temozolomide and interferon alpha2b in metastatic melanoma stage IV

“…In this study we examined tolerability, remission rates and outcome in patients with metastatic melanoma stage IV treated with a combination of temozolomide and IFN‐α2b, the latter in two different dosages. Our patient group showed a slight predominance of male patients, as is often found in series of patients with metastatic melanoma 4,24 , 25,33–35 . The mean age in our study was in the upper range (57·6 years) compared with many other studies, 4,5,12,13,24–26,33–37 ranging between 41 and 58·8 years.…”

“…In the literature, soft tissue metastases are most common, followed by lung, lymph node, brain and bone metastases 4,15 , 24,34 , 35,38 . The percentage of patients with liver metastases ranges between 20% and 39% 4,24 , 25,34 , 35,38 .…”

Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma

“…However, the toxicities of high‐dose IL‐2 are rather intolerable, and intensive care is needed to manage its toxicity . Subcutaneous low‐dose IL‐2 for metastatic melanoma is tolerable and can be used in an outpatient setting . It can also be combined with cytotoxic agents or other cytokines such as interferon‐α.…”

Vaccine Strategies for Glioblastoma: Progress and Future Directions

“…Trials of chemotherapy and systemically delivered IL-2 in other tumors, however, have been generally disappointing [90–92]. This is perhaps not surprising in light of the preclinical studies discussed above and the well-established role of autocrine IL-2 signaling in CD8 T-cell function [93].…”